BioSpace News Archive

Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has completed the synthesis of four different potential inhibitors of Coronavirus protease.

Perrigo Company plc, a leading global provider of Quality, Affordable Self-Care Products, announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host virtual one-on-one meetings at the Barclay’s Global Consumer Staples Conference on Wednesday, September 9, 2020.

EpiVax, Inc. (“EpiVax”), a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (“EVT”), a New York-based company previously named EpiVax Oncology.

Virtual Pharma Expo is back! After resounding success of May 2020’s event with over 1,100 attendees, VertMarkets, Inc.'s Pharmaceutical Online and Techceuticals, LLC will combine for a larger, two-day Virtual Pharma Expo on September 15-16, 2020.

AscellaHealth, a national specialty pharmacy benefit manager (SPBMTM) serving commercial, Medicare and Medicaid segments, announces today its strategic collaboration with Summit Reinsurance Services, Inc. (Summit Re), a managing general underwriter and reinsurance advisor, to provide innovative specialty drug programs to address the high costs of specialty pharmacy claims.

WITHmyDOC, a healthcare technology company that recently entered the remote patient monitoring (RPM) market, has been awarded a Microsoft Global Social Entrepreneurship Grant to assist in its cloud technology utilization

The American Urological Association (AUA) and the Urology Care Foundation—the official foundation of the AUA—today announced Simpa Salami, MD, MPH as the recipient of the 2020 Rising Stars in Urology Research Award.

Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Orphan Drug Designation (ODD) for SLS-005 in mucopolysaccharidosis type III (MPS III), Sanfilippo syndrome, from the European Medicines Agency (EMA).

Summer is Lyme disease season; and while no age group is immune from potential infection, the disproportionate incidents in children is a stark reality that needs addressing.